USAID's Neglected Tropical Diseases' (NTDs) goal under Global Health Initiative (GHI) is to reduce the prevalence of seven NTDs by 50 percent among 70 percent of affected population. With this goal, the project targets to contribute to the elimination of onchocerciasis in the Americas by 2016, the elimination of lymphatic filariasis globally by 2020, and the elimination of blinding trachoma globally by 2020. The NTDs Program relies heavily on generous drug donations from pharmaceutical donation programs. Over $3.1 billion worth of drugs for NTD control have been donated by the pharmaceutical industry to the countries where USAID supported mass drug administration (MDA) campaigns. Four of the drugs needed to treat NTDs, albendazole, mebendazole, Mectizan® and Zithromax®, are donated by GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer, respectively. USAID coordinates closely with these pharmaceutical partners, leveraging their drug donations for USAID-supported MDAs and extending the reach of the donation programs.